Last updated: February 19, 2026
Cosentyx (secukinumab), developed by Novartis, is an interleukin-17A (IL-17A) inhibitor approved for multiple inflammatory conditions. Current clinical trial activity focuses on expanding its therapeutic reach and assessing its long-term efficacy and safety across various indications and patient subgroups. Market analysis indicates continued growth driven by its established efficacy, broad label, and Novartis's strategic market access initiatives, despite increasing competition. Projections anticipate sustained market leadership, contingent on ongoing data generation and favorable regulatory and reimbursement landscapes.
What is the current regulatory status and global approval landscape for Cosentyx?
Cosentyx is approved in over 80 countries for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and, more recently, active non-radiographic axial spondyloarthritis and moderate to severe hidradenitis suppurativa [1, 2, 3]. The U.S. Food and Drug Administration (FDA) first approved Cosentyx in January 2015 for plaque psoriasis. Subsequent approvals expanded its indications to psoriatic arthritis in January 2016, ankylosing spondylitis in November 2015, and active non-radiographic axial spondyloarthritis in January 2020 [1]. In August 2023, the FDA approved Cosentyx for moderate to severe hidradenitis suppurativa, marking its sixth approved indication in the United States [3]. The European Medicines Agency (EMA) has also granted multiple approvals, aligning with or preceding FDA authorizations for these indications [2].
What are the key ongoing clinical trials and their objectives for Cosentyx?
Novartis is actively conducting numerous clinical trials for Cosentyx, aiming to solidify its position and expand its utility. These trials encompass a range of objectives, including:
Table 1: Selected Ongoing Cosentyx Clinical Trials
| Trial Name/Number |
Indication |
Phase |
Primary Objective |
Status |
| SUNSHINE/SUNRISE |
Hidradenitis Suppurativa |
III |
Efficacy and safety of secukinumab in moderate to severe hidradenitis suppurativa |
Active |
| LUPUS-2/LUPUS-3 |
Systemic Lupus Erythematosus |
II/III |
Efficacy and safety of secukinumab in patients with active SLE |
Active |
| PRESCIENT |
Plaque Psoriasis (Extension) |
IV |
Long-term safety and efficacy of secukinumab in moderate to severe plaque psoriasis |
Active |
| MEASURE 2 ext. |
Ankylosing Spondylitis (Ext.) |
IV |
Long-term safety and efficacy of secukinumab in ankylosing spondylitis |
Active |
| EXSTENT |
Psoriatic Arthritis (Extension) |
IV |
Long-term safety and efficacy of secukinumab in psoriatic arthritis |
Active |
Data based on clinicaltrials.gov and company reports. Status reflects current publicly available information and may evolve.
What is the current market performance of Cosentyx?
Cosentyx has established itself as a leading biologic therapy across its approved indications, demonstrating robust commercial success.
- Sales Trajectory: Cosentyx has experienced a significant and consistent sales growth since its launch. In 2023, net sales reached $5.16 billion, an increase of 8% compared to $4.79 billion in 2022 [7]. This growth trajectory underscores its strong market penetration and patient uptake.
- Indication Contributions: While plaque psoriasis remains a cornerstone indication, growth has been significantly driven by its expanding use in psoriatic arthritis and ankylosing spondylitis. The recent approval for hidradenitis suppurativa represents a new growth avenue.
- Geographic Performance: Cosentyx shows strong performance in key markets, including the United States and Europe, with increasing contributions from emerging markets as Novartis expands its global reach and market access.
- Competitive Landscape: Cosentyx competes with other biologic agents, including other IL-17 inhibitors (e.g., ixekizumab), TNF inhibitors, and IL-23 inhibitors, across its indications. Its broad label and established safety and efficacy profile have allowed it to maintain a significant market share.
- Market Access and Reimbursement: Novartis has actively pursued broad market access and favorable reimbursement for Cosentyx, which has been a critical factor in its commercial success.
Table 2: Cosentyx Annual Net Sales Performance (USD Billions)
| Year |
Net Sales (USD Billions) |
Year-over-Year Growth |
| 2020 |
4.07 |
28% |
| 2021 |
4.52 |
11% |
| 2022 |
4.79 |
6% |
| 2023 |
5.16 |
8% |
Data sourced from Novartis annual reports and financial statements.
What are the projected market trends and future opportunities for Cosentyx?
The future market outlook for Cosentyx remains positive, driven by several key factors, though competitive pressures will intensify.
- Sustained Growth in Established Indications: Cosentyx is expected to maintain its leadership in plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis due to its proven efficacy, convenient dosing (including a once-monthly subcutaneous injection option after initial loading), and a growing body of real-world evidence.
- New Indication Expansion: The approval and ongoing development for hidradenitis suppurativa represent a significant growth opportunity. Successful penetration into this market, where treatment options are limited, could add substantial revenue. Further exploration in indications like lupus, if successful in late-stage trials, could significantly broaden its market potential.
- Competition: The market for autoimmune and inflammatory diseases is highly competitive. The emergence of new IL-23 inhibitors and other novel biologics with potentially superior efficacy or convenience in specific patient populations will challenge Cosentyx's market share.
- Biosimilar and Generic Threat: While Cosentyx is a biologic and not subject to traditional generic competition, the eventual expiry of patents could open the door for biosimilar development. However, given its complex manufacturing and the established brand loyalty, the impact of biosimilars may be less immediate compared to small-molecule drugs.
- Geographic Expansion: Continued efforts to penetrate emerging markets and secure favorable reimbursement in new territories will be crucial for sustaining global sales growth.
- Real-World Evidence: The generation and dissemination of real-world evidence demonstrating long-term effectiveness, safety, and patient-reported outcomes will be critical for reinforcing its value proposition to healthcare providers, payers, and patients.
Projected Market Performance: Analysts project Cosentyx’s sales to continue growing, potentially exceeding $6 billion annually in the coming years, contingent on the success of its pipeline and the competitive response. The expansion into HS and potential approval in other autoimmune diseases are key upside drivers.
What are the key challenges and risks for Cosentyx?
Despite its strong market position, Cosentyx faces several challenges and risks that could impact its future performance:
- Intensifying Competition: The autoimmune and inflammatory disease landscape is dynamic, with numerous companies developing and launching new biologic and small-molecule therapies. These competitors often aim to offer improved efficacy, safety profiles, or novel mechanisms of action. For instance, newer IL-23 inhibitors have demonstrated strong efficacy in psoriasis and psoriatic arthritis.
- Pricing Pressure and Reimbursement Hurdles: Healthcare systems globally face increasing pressure to control costs. This can lead to tighter reimbursement policies, prior authorization requirements, and formulary restrictions, which can limit patient access to Cosentyx.
- Adherence and Administration: While Cosentyx offers convenient dosing, adherence to chronic injectable therapies can remain a challenge for some patients. Patient education and support programs are crucial for mitigating this risk.
- Adverse Event Profile: Like all biologics, Cosentyx carries a risk of adverse events, including infections. Ongoing monitoring and transparent communication of its safety profile are essential. Any significant new safety signals could impact its market perception and regulatory standing.
- Patent Expirations and Biosimilar Entry: While patent protection provides a period of market exclusivity, the eventual expiration of key patents will open the door for biosimilar competition. The timing and impact of biosimilar entry will depend on regulatory pathways and manufacturing complexities.
- Pipeline Execution: The success of Cosentyx in new indications, such as lupus, is critical for its long-term growth. Any clinical trial failures or delays in regulatory approvals for these new indications would represent a significant setback.
Key Takeaways
Cosentyx maintains a robust market position driven by its established efficacy across multiple inflammatory diseases, broad regulatory approvals, and strategic commercialization by Novartis. Ongoing clinical trials are focused on expanding its therapeutic indications, particularly in hidradenitis suppurativa and systemic lupus erythematosus, and on generating long-term safety and efficacy data. While projected to achieve sustained sales growth, Cosentyx faces intensifying competition from newer biologic agents, potential pricing pressures, and the future threat of biosimilar entry. Successful execution of its pipeline development and effective navigation of the evolving market access landscape will be critical for its continued commercial success.
Frequently Asked Questions
-
What is the primary mechanism of action for Cosentyx?
Cosentyx is a fully human monoclonal antibody that selectively targets the p19 subunit of interleukin-17A (IL-17A). By inhibiting IL-17A, it blocks downstream signaling pathways that are key drivers of inflammation in several autoimmune and inflammatory diseases.
-
What are the most significant new indications for Cosentyx currently being explored in clinical trials?
Novartis is actively developing Cosentyx for systemic lupus erythematosus (SLE) and has recently gained approval for moderate to severe hidradenitis suppurativa (HS). These represent key growth opportunities beyond its established indications.
-
How does Cosentyx compare in terms of dosing frequency to other leading biologics for psoriasis?
After an initial loading phase, Cosentyx is typically administered once every four weeks via subcutaneous injection. Some patients may transition to a bi-monthly dosing regimen depending on disease severity and response. This dosing frequency is generally competitive among advanced biologic therapies.
-
What is the projected timeline for potential biosimilar entry for Cosentyx?
The exact timeline for biosimilar entry depends on patent expiry dates and the regulatory approval processes in different regions. While specific dates vary, key patents are expected to expire over the next decade, potentially paving the way for biosimilar competition in the late 2020s and beyond.
-
Beyond plaque psoriasis and psoriatic arthritis, which other major indications contribute significantly to Cosentyx's market share?
Ankylosing spondylitis and active non-radiographic axial spondyloarthritis are also significant contributors to Cosentyx's market share, demonstrating its efficacy in treating axial inflammatory arthritis. The recent approval for hidradenitis suppurativa is expected to become an increasingly important revenue driver.
Citations
[1] U.S. Food and Drug Administration. (n.d.). Drug Approval Packages. Retrieved from [FDA website] (Specific drug approval information is accessible via the FDA's drug database, search for Cosentyx.)
[2] European Medicines Agency. (n.d.). European Public Assessment Reports. Retrieved from [EMA website] (Specific drug assessment reports are available on the EMA's website.)
[3] Novartis AG. (2023, August 3). FDA approves Cosentyx® (secukinumab) for moderate to severe hidradenitis suppurativa. [Press Release].
[4] ClinicalTrials.gov. (n.d.). Search Results for Secukinumab Hidradenitis Suppurativa. Retrieved from [ClinicalTrials.gov website]
[5] ClinicalTrials.gov. (n.d.). Search Results for Secukinumab Lupus. Retrieved from [ClinicalTrials.gov website]
[6] ClinicalTrials.gov. (n.d.). Search Results for Secukinumab Extension Studies. Retrieved from [ClinicalTrials.gov website]
[7] Novartis AG. (2024, January 31). Novartis announces full-year 2023 results. [Press Release].
